Sandra Rea

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.

Journal: NPJ breast cancer
Published: January 23, 2026

Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review.

Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review.

Journal: Biology direct
Published: May 02, 2025

Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors.

Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors.

Journal: Frontiers in oncology
Published: March 24, 2023

Correction to: Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.

Correction to: Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.

Journal: European radiology
Published: March 09, 2022

A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either 64CuCl2 or 64CuPSMA PET/CT.

A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either 64CuCl2 or 64CuPSMA PET/CT.

Journal: Cancers
Published: September 08, 2021

Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.

Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.

Journal: European radiology
Published: June 02, 2021

Bone density and genomic analysis unfold cold adaptation mechanisms of ancient inhabitants of Tierra del Fuego.

Bone density and genomic analysis unfold cold adaptation mechanisms of ancient inhabitants of Tierra del Fuego.

Journal: Scientific reports
Published: May 06, 2021

The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study.

The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study.

Journal: Journal of experimental & clinical cancer research : CR
Published: April 19, 2021

Thrombosis of the Iliac Vein Detected by 64Cu-Prostate-Specific Membrane Antigen (PSMA) PET/CT.

Thrombosis of the Iliac Vein Detected by 64Cu-Prostate-Specific Membrane Antigen (PSMA) PET/CT.

Journal: Clinical nuclear medicine
Published: October 08, 2020

Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center.

Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center.

Journal: Journal of clinical medicine
Published: June 25, 2020

Dual-time 18F-FDG PET/CT for the detection of liver metastases in breast cancer.

Dual-time 18F-FDG PET/CT for the detection of liver metastases in breast cancer.

Journal: Nuclear medicine communications
Published: September 15, 2018

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma.

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma.

Journal: Experimental hematology & oncology
Published: March 20, 2015
Showing 1-12 of 14

Last Updated: 09/26/2026